Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 1588

TitleReference numberPublishedLast updated
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Overweight and obesity managementQS212
Single-step scaffold insertion for repairing symptomatic chondral knee defectsHTG728
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessmentHTG756
Cardiovascular risk assessment and lipid modificationQS100
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
One-piece closed bags for colostomies: late-stage assessmentHTG754
Pulsed-field ablation for atrial fibrillationHTG755
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessmentHTG753
Dapagliflozin for treating chronic kidney diseaseTA1075
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitationHTG752
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessmentHTG751
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Targeted muscle reinnervation for managing limb amputation painHTG750
Caesarean birthNG192
Linzagolix for treating symptoms of endometriosisTA1067
Efgartigimod for treating antibody-positive generalised myasthenia gravisTA1069
Headaches in over 12s: diagnosis and managementCG150
Somapacitan for treating growth hormone deficiency in people 3 to 17 yearsTA1066
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux diseaseHTG749
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)TA1068
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA1065
Abortion careNG140
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA1064
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentTA1063
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphomaTA1059
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessmentHTG748
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Drug-eluting stents for treating coronary artery disease: late-stage assessmentHTG747
COVID-19 rapid guideline: managing COVID-19NG191
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTG746
Slide sheets for moving or repositioning a person: late-stage assessmentHTG745
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249

Results per page

  1. 10
  2. 25
  3. 50
  4. All